seroprotection

seroprotection

(sēr″ō-prō-tĕk′shŭn)
An antibody response capable of preventing infection, e.g., after a vaccination or a previous infection with a microorganism.
References in periodicals archive ?
Halperin indicated that 100% of all subjects were seroprotected at month three (3) and that all subjects sustained seroprotection at month eight (8).
In the expanded Australian clinical trial, studies will determine whether seasonal vaccine co-administered with the experimental therapeutic Ampligen[R], may provide long-lasting seroprotection against either/both of the emerging strains of H5N1.
A 2-3-year follow-up of 186 infants vaccinated in 1995 with Hepaccine B showed seroprotection (anti-hepatitis B surface antibody (anti-HBsAb) [greater than or equal to] 10 mIU/ml) in 93% and 76.
1 Heplisav (Dynavax Technologies): Higher Seroprotection Levels 6.
Unpublished data from the Centers for Disease Control and Prevention suggest that diabetes patients experience a similar drop in seroprotection with age (80% at 41-59 years, 65% at 60-69 years, and less than 40% at 70 years and older), he noted.
Seroprotection was defined as having HAI antibody titers of [greater than or equal to] 40.
This new Japanese encephalitis vaccine has shown to provide seroprotection to 96% of the children just 1 month after one dose and long term protection after a booster [sup.
In this subset of 500 subjects from stage A, the hemagglutinin inhibition (HAI) antibody titers 14 days post dose one in the 15 and 45 [micro]g arms met the serocon version an d seroprotection criteria recommended by the U.
In this subset of 500 subjects from Stage A, the hemagglutinin inhibition (HAI) antibody titers 14 days post dose one in the 15 and 45 mcg arms met the seroconversion and seroprotection criteria recommended by the U.
A smaller percentage of the transplant patients achieved seroresponse or seroprotection than the healthy controls.
55,56) In one study, a hepatitis B seroprotection rate of 85% was observed 2 months after administration of combination hepatitis A and hepatitis B vaccine to healthy adults at days 0, 7, and 21.
In a statement yesterday Novartis said: "Results showed that various levels mandated by European regulators for seroprotection, seroconversion increase and mean geometric increase of H5N1-specific antibodies were achieved.